This article first appeared on GuruFocus.
Portfolio Quality: Current portfolio proportion increased from 81.67% in September to 81.77% in December.
Collection Efficiency: Unique customer collection efficiency stable at 95.1%; overall collection efficiency at 96.6%.
Unique Customer Collection Efficiency (Excluding NPA):
Achieved $28.2 million in RYTELO™ (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million …
– Received U.S. Food and Drug Administration (“FDA”) Breakthrough Therapy Designation (“BTD”) for CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of Major Depressive Disorder (“MDD”) –
– Clinical site selection complete for Phase 3 multinational
